Skip to main content
Article thumbnail
Location of Repository

Preliminary evaluation of a bunyavirus vector for cancer immunotherapy

By N. Oreshkova, L. Spel, R. P M Vloet, P. J. Wichgers Schreur, R. J M Moormann, M. Boes and J. Kortekaas


Replicon particles of Rift Valley fever virus, referred to as nonspreading Rift Valley fever virus (NSR), are intrinsically safe and highly immunogenic. Here, we demonstrate that NSR-infected human dendritic cells can activate CD8<sup>+</sup> T cells in vitro and that prophylactic and therapeutic vaccinations of mice with NSR encoding a tumor-associated CD8 peptide can control the outgrowth of lymphoma cells in vivo. These results suggest that the NSR system holds promise for cancer immunotherapy

Topics: Immunology, Virology
Year: 2015
OAI identifier:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.